Skip to main content
An official website of the United States government

autologous PRAME-targeting TCR-modified T cells MDG1011

Human autologous T lymphocytes transduced with a retroviral vector encoding a human leukocyte antigen (HLA)-A*02:01-restricted T-cell receptor (TCR) specific for the human tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) coupled to the CD3 signaling complex, with potential antineoplastic activity. Upon reintroduction into the patient, the autologous PRAME-targeting TCR-modified T cells MDG1011 target and bind to tumor cells expressing PRAME. This may induce cell death in and halt the growth of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.
Synonym:autologous anti-PRAME-TCR-expressing T cells MDG1011
autologous PRAME TCR-modified T cells MDG1011
autologous TCR-modified T cells MDG1011
PRAME-TCR gene-modified autologous T cells MDG1011
Code name:MDG 1011
MDG-1011
MDG1011
Search NCI's Drug Dictionary